Sartorius Stedim Biotech Launches Sartoguard NF Prefilter Series
Published: Apr 11, 2013
Sartoguard NF prefilters are the ideal choice for downstream protection of more expensive sterilizing-grade and Mycoplasma-retentive filters in challenging prefiltration applications for biopharmaceutical manufacturing. In combination with their high total throughput performance, Sartoguard NF prefilters offer significant cost-saving potential due to their ultrafine retention performance, which ensures removal even of extremely small particulatebased contaminants. All active filter materials – membranes and nanofleece – of the new prefilter series are made of polyethersulfone, thus ensuring a minimum extractable footprint. This enables users to easily implement Sartoguard NF into existing filtration processes utilizing final filters already based on PES.
Sartoguard NF filter elements are available in all common filter formats offered by Sartorius Stedim Biotech, such as SartoScale devices for small-scale filterability trials, as well as MidiCaps, MaxiCaps and standard filter cartridges for medium- and commercial-scale manufacturing. Sartoguard NF MidiCaps and MaxiCaps are the first fully gamma irradiatable prefilter series and can be easily integrated into single-use process equipment.
Sartoguard NF filters conclude the launch of the Sartoguard prefilter family, which includes the Sartoguard PES and Sartoguard GF prefilter series that have been successfully introduced to the market earlier. The launch of the Sartoguard prefilter family is an important contribution by Sartorius Stedim Biotech in reducing overall filtration costs in biopharmaceutical manufacturing and in helping biomanufacturers cope with the increasing cost pressure while maintaining and improving their high quality standards.
Figure: The new Sartoguard NF prefilter series combines high flow rates and total throughput performance
Download Link: www.sartorius.com/fileadmin/media/global/company/Sartoguard-NF.jpg
About Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.” Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 2,850 people, and in 2011 earned sales revenue of 477.,3 million euros.